Get Details

Winston Kung

Winston is currently the Chief Financial Officer at ArriVent BioPharma. Prior to joining ArriVent BioPharma, Mr. Kung was the Chief Financial Officer and Chief Operating Officer at PMV Pharma. Prior to joining PMV Pharma, Mr. Kung was a Vice President of Business Development and Global Alliances at Celgene and Chief Business Officer at Celgene Cellular Therapeutics (CCT). While at Celgene, he led the strategic long-range plan formation, multiple transactions, equity investments, company integrations, and a team that managed Celgene’s alliance portfolio of more than 100 collaborations. Prior to Celgene, Mr. Kung worked from 2007 to 2013 at Citigroup in its Global Healthcare Investment Banking group and Lehman Brothers (which was subsequently acquired by Barclays) in its Global Mergers and Acquisition Group. He worked on various transactions including public and private financings, mergers, acquisitions, spin-outs and other financial advisory engagements.

From 2004 to 2007, Mr. Kung served at Amgen as a cofounder of the Alliance Management group and also served as the deal lead on multiple acquisitions as part of the Corporate Development group. He was also part of the Business and Corporate Development group at Genentech. He worked on several transactions, including leading the spin-out of Tercica (acquired by Ipsen), and co-led the formation of the Genenfund, Genentech’s first Corporate Venture Capital Fund. He received his MBA from Harvard Business School, and his A.B. in Biology and A.B in International Relations with honors from Brown University.

Let’s do some great work together to bring game-changing medicines to patients.